According to a new study, topical calcineurin inhibitors such as pimecrolimus and tacrolimus did not increase cancer risk in atopic dermatitis (AD) patients.
top of page
it's where dermatology lives
bottom of page
According to a new study, topical calcineurin inhibitors such as pimecrolimus and tacrolimus did not increase cancer risk in atopic dermatitis (AD) patients.